Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans

Cancer Immunology, Immunotherapy

Volumn 58, Issue 1, 2009, Pages 95-109

  Amann, Maria ^a,b   Friedrich, Matthias ^a,b   Lutterbuese, Petra ^a,b   Vieser, Eva ^a,b   Lorenczewski, Grit ^a,b   Petersen, Laetitia ^a,b   Brischwein, Klaus ^a,b   Kufer, Peter ^a,b   Kischel, Roman ^a,b   Baeuerle, Patrick A ^a,b   Schlereth, Bernd ^a,b  

^a MICROMET AG   (Germany)

^b Micromet Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; BITE ANTIBODY; CD3 ANTIBODY; EPITHELIAL CELL ADHESION MOLECULE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MUS110; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL SUBPOPULATION; CONTROLLED STUDY; CYTOKINE RELEASE; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPOTHERMIA; LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REFLEX; T LYMPHOCYTE ACTIVATION; WEIGHT REDUCTION;

ANIMALS; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; CRICETULUS; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RECOMBINANT PROTEINS; SPECIES SPECIFICITY;

EID: 54849440117     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-008-0529-y     Document Type: Article

References (47)

1. M Alegre M Depierreux S Florquin T Najdovski P Vandenabeele D Abramowicz O Leo M Deschodt-Lanckman M Goldman 1990 Acute toxicity of anti-CD3 monoclonal antibody in mice: a model for OKT3 first dose reactions Transplant Proc 22 1920 1921
2. M Alegre P Vandenabeele V Flamand M Moser O Leo D Abramowicz J Urbain W Fiers M Goldman 1990 Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: role of tumor necrosis factor Eur J Immunol 20 707 710
3. ML Alegre P Vandenabeele M Depierreux S Florquin M Deschodt-Lanckman V Flamand M Moser O Leo J Urbain W Fiers 1991 Cytokine release syndrome induced by the 145-2C11 anti-CD3 monoclonal antibody in mice: prevention by high doses of methylprednisolone J Immunol 146 1184 1191
4. M Amann K Brischwein P Lutterbuese L Parr L Petersen G Lorenczewski E Krinner S Bruckmeier S Lippold R Kischel R Lutterbuese P Kufer PA Baeuerle B Schlereth 2008 Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3 Cancer Res 68 143 151
5. A Ariel EJ Yavin R Hershkoviz A Avron S Franitza I Hardan L Cahalon M Fridkin O Lider 1998 IL-2 induces T cell adherence to extracellular matrix: inhibition of adherence and migration by IL-2 peptides generated by leukocyte elastase J Immunol 161 2465 2472
6. PA Baeuerle O Gires 2007 EpCAM (CD326) finding its role in cancer Br J Cancer 96 417 423
7. PA Baeuerle C Reinhardt P Kufer 2008 BiTE: a new class of antibodies that recruit T-cells Drugs Future 33 2 1 11
8. Bargou R, Noppeney R, Schuler M, Hess G, Gerecke C, Zettl F, Birkmann J, Viardot A, Kirchinger P, Baeuerle P, Reinhardt C, Klinger M, Libicher M, Goebeler M, Einsele H, Kufer P, Zugmaier G, Leo E (2006) The bi-specific T-cell enhancer (BiTE) MT103 (MEDI-538) induces clinical responses in heavily pre-treated NHL patients: update from the ongoing phase I study MT103-104. Blood 108:693 (ASH Annual Meeting Abstracts)
9. RC Bargou P Kufer M Goebeler S Knop H Einsele R Noppeney A Viardot G Hess G Riethmueller D Reitsma E Leo C Reinhardt G Zugmaier 2007 The anti-CD19 bispecific T-cell engager (BiTE) MT103 (MEDI-538), induces dose-dependent complete and partial responses in relapsed Non-Hodgkin Lymphoma (NHL): phase I study MT103-104 ASH Annu Meet Abstr 110 2557
10. PJ Barnes 1998 Anti-inflammatory actions of glucocorticoids: molecular mechanisms Clin Sci (Lond) 94 557 572
11. TS Blackwell JW Christman 1996 Sepsis and cytokines: current status Br J Anaesth 77 110 117
12. TA Borkowski AJ Nelson AG Farr MC Udey 1996 Expression of gp40, the murine homologue of human epithelial cell adhesion molecule (Ep-CAM), by murine dendritic cells Eur J Immunol 26 110 114
13. C Brandl C Haas S d'Argouges T Fisch P Kufer K Brischwein N Prang R Bargou J Suzich PA Baeuerle R Hofmeister 2007 The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19/CD3-bispecific single-chain antibody construct Cancer Immunol Immunother 56 1551 1563
14. K Brischwein B Schlereth B Guller C Steiger A Wolf R Lutterbuese S Offner M Locher T Urbig T Raum P Kleindienst P Wimberger R Kimmig I Fichtner P Kufer R Hofmeister AJ da Silva PA Baeuerle 2006 MT110: a novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors Mol Immunol 43 1129 1143
15. K Brischwein L Parr S Pflanz J Volkland J Lumsden M Klinger M Locher SA Hammond P Kiener P Kufer B Schlereth PA Baeuerle 2007 Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class J Immunother 30 798 807
16. S Buysmann FJ Bemelman PT Schellekens Y van Kooyk CG Figdor IJ ten Berge 1996 Activation and increased expression of adhesion molecules on peripheral blood lymphocytes is a mechanism for the immediate lymphocytopenia after administration of OKT3 Blood 87 404 411
17. PJ Carter 2006 Potent antibody therapeutics by design Nat Rev Immunol 6 343 357
18. B Charpentier C Hiesse C Ferran O Lantz D Fries JF Bach L Chatenoud 1991 Acute clinical syndrome associated with OKT3 administration. Prevention by single injection of an anti-human TNF monoclonal antibody Presse Med 20 2009 2011
19. L Chatenoud C Ferran JF Bach 1991 The anti-CD3-induced syndrome: a consequence of massive in vivo cell activation Curr Top Microbiol Immunol 174 121 134
20. L Chatenoud C Legendre C Ferran JF Bach H Kreis 1991 Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome-dosage and kinetics prerequisites Transplantation 51 334 338
21. JR Desjarlais GA Lazar EA Zhukovsky SY Chu 2007 Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective Drug Discov Today 12 898 910
22. C Ferran M Dy K Sheehan S Merite R Schreiber P Landais G Grau J Bluestone JF Bach L Chatenoud 1991 Inter-mouse strain differences in the in vivo anti-CD3 induced cytokine release Clin Exp Immunol 86 537 543
23. H Gottlinger J Johnson G Riethmuller 1986 Biochemical and epitope analysis of the 17-1A membrane antigen Hybridoma 5 Suppl 1 S29 S37
24. DM Green J Trial HH Birdsall 1998 TNF-alpha released by comigrating monocytes promotes transendothelial migration of activated lymphocytes J Immunol 161 2481 2489
25. R Hayashi H Wada K Ito IM Adcock 2004 Effects of glucocorticoids on gene transcription Eur J Pharmacol 500 51 62
26. R Hirsch RE Gress DH Pluznik M Eckhaus JA Bluestone 1989 Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells J Immunol 142 737 743
27. RJ Kaufman 1990 Selection and coamplification of heterologous genes in mammalian cells Methods Enzymol 185 537 566
28. Klinger M, Kufer P, Kirchinger P, Lutterbuse R, Leo E, Reinhardt C, Bauerle P and Bargou R (2006) T cell responses during long-term continuous infusion of MT103 (MEDI-538; anti-CD19 BiTE) in patients with relapsed B-NHL: data from dose-escalation study MT103-104. Blood 108:2725 (ASH Annual Meeting Abstracts)
29. RE Kontermann 2005 Recombinant bispecific antibodies for cancer therapy Acta Pharmacol Sin 26 1 9
30. P Kufer F Zettl K Borschert R Lutterbuse R Kischel G Riethmuller 2001 Minimal costimulatory requirements for T cell priming and TH1 differentiation: activation of naive human T lymphocytes by tumor cells armed with bifunctional antibody constructs Cancer Immunol 1 10
31. JM Lambert 2005 Drug-conjugated monoclonal antibodies for the treatment of cancer Curr Opin Pharmacol 5 543 549
32. M Mack G Riethmuller P Kufer 1995 A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity Proc Natl Acad Sci USA 92 7021 7025
33. T Miyamoto T Fujinaga K Yamashita M Hagio 1996 Changes of serum cytokine activities and other parameters in dogs with experimentally induced endotoxic shock Jpn J Vet Res 44 107 118
34. G Moldenhauer F Momburg P Moller R Schwartz GJ Hammerling 1987 Epithelium-specific surface glycoprotein of Mr 34, 000 is a widely distributed human carcinoma marker Br J Cancer 56 714 721
35. AJ Nelson RJ Dunn R Peach A Aruffo AG Farr 1996 The murine homolog of human Ep-CAM, a homotypic adhesion molecule, is expressed by thymocytes and thymic epithelial cells Eur J Immunol 26 401 408
36. MC Panelli R White M Foster B Martin E Wang K Smith FM Marincola 2004 Forecasting the cytokine storm following systemic interleukin (IL)-2 administration J Transl Med 2 17
37. CG Rao D Chianese GV Doyle MC Miller T Russell RA Sanders Jr LW Terstappen 2005 Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors Int J Oncol 27 49 57
38. T Raum R Gruber G Riethmuller P Kufer 2001 Anti-self antibodies selected from a human IgD heavy chain repertoire: a novel approach to generate therapeutic human antibodies against tumor-associated differentiation antigens Cancer Immunol Immunother 50 141 150
39. B Schlereth I Fichtner G Lorenczewski P Kleindienst K Brischwein A da Silva P Kufer R Lutterbuese I Junghahn S Kasimir-Bauer P Wimberger R Kimmig PA Baeuerle 2005 Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct Cancer Res 65 2882 2889
40. B Schlereth P Kleindienst I Fichtner G Lorenczewski K Brischwein S Lippold A da Silva M Locher R Kischel R Lutterbuse P Kufer PA Baeuerle 2006 Potent inhibition of local and disseminated tumor growth in immunocompetent mouse models by a bispecific antibody construct specific for Murine CD3 Cancer Immunol Immunother 55 785 796
41. B Schlereth C Quadt T Dreier P Kufer G Lorenczewski N Prang C Brandl S Lippold K Cobb K Brasky E Leo R Bargou K Murthy PA Baeuerle 2006 T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct Cancer Immunol Immunother 55 503 514
42. M Stern R Herrmann 2005 Overview of monoclonal antibodies in cancer therapy: present and promise Crit Rev Oncol Hematol 54 11 29
43. JE Talmadge O Bowersox H Tribble SH Lee HM Shepard D Liggitt 1987 Toxicity of tumor necrosis factor is synergistic with gamma-interferon and can be reduced with cyclooxygenase inhibitors Am J Pathol 128 410 425
44. LM Weiner 2000 Bispecific antibodies in cancer therapy Cancer J 6 Suppl 3 S265 S271
45. P Went M Vasei L Bubendorf L Terracciano L Tornillo U Riede J Kononen R Simon G Sauter PA Baeuerle 2006 Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers Br J Cancer 94 128 135
46. KM Wissing F Desalle D Abramowicz F Willems O Leo M Goldman ML Alegre 1999 Down-regulation of interleukin-2 and interferon-gamma and maintenance of interleukin-4 and interleukin-10 production after administration of an anti-CD3 monoclonal antibody in mice Transplantation 68 677 684
47. E Wolf R Hofmeister P Kufer B Schlereth PA Baeuerle 2005 BiTEs: bispecific antibody constructs with unique anti-tumor activity Drug Discov Today 10 1237 1244